945493-87-8

Basic information

• Product Name: GSK 189254
• Synonyms: GSK 189254;6-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride;6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]-N-methylpyridine-3-carboxamide:hydrochloride
• CAS NO: 945493-87-8
• Molecular Formula: C₂₁H₂₅N₃O₂*ClH
• Molecular Weight: 387.90304
• Mol File: 945493-87-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: GSK 189254(CAS DataBase Reference)
• NIST Chemistry Reference: GSK 189254(945493-87-8)
• EPA Substance Registry System: GSK 189254(945493-87-8)

Safety Data

• Hazardous Substances Data: 945493-87-8(Hazardous Substances Data)

Usage

General Description

GSK 189254 is a selective and potent antagonist of the histamine H3 receptor, which is a G protein-coupled receptor that is primarily expressed in the central nervous system. This receptor is involved in the regulation of neurotransmitter release, and antagonists of the H3 receptor have been studied for their potential as treatments for various central nervous system disorders, including cognitive deficits, sleep disorders, and obesity. GSK 189254 has shown promising results in preclinical studies, demonstrating improvements in cognitive function and wakefulness in animal models. It is currently being investigated as a potential treatment for cognitive deficits associated with conditions such as Alzheimer's disease and schizophrenia. Note: This is a hypothetical summary and may not reflect the current state of research on GSK 189254.

Upstream product

• 720690-73-3 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide 

Relevant articles and documents

NOVEL DOSAGE FORM

The present invention relates to a novel dosage form, to a process for preparing the dosage form and to the use of the dosage form in the treatment of neurological and psychiatric disorders.